With 0.81 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.05 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $21.64 whereas the lowest price it dropped to was $20.245. The 52-week range on SGRY shows that it touched its highest point at $35.29 and its lowest point at $19.50 during that stretch. It currently has a 1-year price target of $33.45. Beta for the stock currently stands at 2.60.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGRY was down-trending over the past week, with a drop of -1.96%, but this was down by -8.84% over a month. Three-month performance dropped to -34.11% while six-month performance fell -11.05%. The stock lost -32.60% in the past year, while it has lost -3.02% so far this year. A look at the trailing 12-month EPS for SGRY yields -0.48 with Next year EPS estimates of 0.95. For the next quarter, that number is 0.37. This implies an EPS growth rate of -15.54% for this year and 12.83% for next year. EPS is expected to grow by 46.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 54.69%.
Float and Shares Shorts:
At present, 127.13 million SGRY shares are outstanding with a float of 73.96 million shares on hand for trading. On 2024-12-13, short shares totaled 10.89 million, which was 857.0 higher than short shares on 1731628800. In addition to Mr. Wayne Scott DeVeydt as the firm’s Executive Chairman, Mr. J. Eric Evans serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 1.1011 of SGRY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SGRY reported revenue of $770400000.0 and operating income of $100300000.0. The EBITDA in the recently reported quarter was $155700000.0 and diluted EPS was -$0.25.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGRY since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SGRY analysts setting a high price target of 40.0 and a low target of 28.0, the average target price over the next 12 months is 33.51917. Based on these targets, SGRY could surge 94.84% to reach the target high and rise by 36.39% to reach the target low. Reaching the average price target will result in a growth of 63.27% from current levels.
Analysts have provided yearly estimates in a range of $0.96355 being high and $0.78511 being low. For SGRY, this leads to a yearly average estimate of $0.84459. Based on analyst estimates, the high estimate for the next quarter is $0.22 and the low estimate is $0.11. The average estimate for the next quarter is thus $0.17.
